Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
BMO Capital Reiterates Biogen (BIIB) at Market Perform, Company's Investor Conference Does Not Invigorate Confidence
-
Needham & Company Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
-
BMO Capital Reiterates Gilead Sciences (GILD) at Market Perform, Sees TROPiCS-02 Results As Not Clinically Meaningful
-
Truist Securities Reiterates Gilead Sciences (GILD) at Hold, TROPiCS-02 is Encouraging, Analyst Sees Potential Upside for Trodelvy
-
Cantor Fitzgerald Reiterates TherapeuticsMD (TXMD) at Overweight, $5 PT, VitaCare Sale is Good News, Priced Above Expectation, Increases Confidence in the Stock
-
Cantor Fitzgerald Reiterates VYNE Therapeutics (VYNE) at Overweight, Newest Data Supports Positive Thesis for Stock
-
Cowen Reiterates Outperform Rating on Gilead Sciences (GILD), Warns Reward on TROPiCS-02 May Not be As Great
-
Cowen Reiterates Outperform Rating on Tyra Biosciences (TYRA)
-
Truist Securities Reiterates Verona Pharma (VRNA) at Buy, "We Like Risk/Benefit Heading into Phase 3 Readout"
-
Cantor Fitzgerald Reiterates Overweight Rating on Evolus (EOLS), Jeuveau's Value Proposition is Underappreciated
-
Needham & Company Reiterates NextCure (NXTC) at Buy, Focus Remains on Upcoming Results of Yale Study
-
Stifel Reiterates Buy Rating on Applied Genetic Technologies Corp. (AGTC)
-
Mizuho Securities Reiterates Evolus (EOLS) at Buy, Sees Room for Significantly More Upside Ahead
-
Stifel Upgrades Orthofix International (OFIX) to Buy, Hikes PT to $45, "Significant Progress Has Been Made Across All Goalposts"
-
Cantor Fitzgerald Reiterates Hutchison China MediTech Ltd. (HCM) at Overweight, Believes HCM's Pipeline is Underappreciated
-
Truist Securities Reiterates argenx SE (ARGX) at Buy, ADAPT-SC Trial Sets Up for Success
-
Cantor Fitzgerald Reiterates EyePoint (EYPT) at Overweight, Believes Potential Peak Sales for EYP-1901 Remains Underappreciated
-
Fulcrum Therapeutics (FULC) PT Lowered to $43 at Stifel
-
Cantor Fitzgerald Reiterates Entasis Therapeutics (ETTX) at Overweight, Believes More Value to Unlocked in Shares
-
Dawson James Reiterates BioCardiAa (BCDA) at Buy on Canada Expansion, Maintains $4 Price Target
-
Stifel Reiterates Buy Rating on Precigen Inc. (PGEN)
-
Repare Therapeutics (RPTX) PT Lowered to $45 at Stifel, Analyst Believes RP-3500 Data Could Improve with More Follow-up Time
-
Stifel Reiterates ChemoCentryx (CCXI) at Buy, Stock Reaction is Overdone, Tavneos Outlook Unchanged
-
Cowen Reiterates Intercept Pharmaceuticals (ICPT) at Market Perform, Believes Company May Hit Temporary Break-even in 2022
-
Truist Securities Reiterates NuCana (NCNA) at Buy, NuTide:121 is Not Central to Thesis, Plenty of Cash Runway to Complete Other Studies
-
Cowen Reiterates Outperform Rating on Avidity Biosciences (RNA)
-
Ascendis Pharma (ASND) PT Lowered to $166 at Oppenheimer, Outperform Reiterated, Skytrofa Metrics Encourage Despite Sales Miss, Remain Positive on TransCon PTH's Phase 3
-
Verrica Pharmaceuticals (VRCA) PT Lowered to $18 at Needham & Company on Financing Overhang, Analyst Notes "Attractive Sales Potential" of Ycanth
-
H.C. Wainwright Reiterates Neutral Rating on Intercept Pharmaceuticals (ICPT)
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $25 at Needham & Company, Analyst Does Not Anticipate Phase 3 REVERSE Trial to Have a Positive Outcome
-
Needham & Company Reiterates Akebia Therapeutics (AKBA) at Buy, Results From INNO2VATE Trial Support Approval of vadadustat
-
Cantor Fitzgerald Reiterates Avalo (AVTX) at Overweight, Peak Sales Potential of Pipeline is Underappreciated
-
Dawson James Reiterates Buy Rating on Check-Cap (CHEK), Assumes Successful Launch of Imaging Capsule in US and EU
-
Dawson James Reiterates Neutral Rating on IsoRay (ISR), Sees Fair Value of Under $1
-
Senseonics Holdings (SENS) PT Slashed to $2.50 at Stifel on Execution Concerns, Analyst Reiterates Faith in Company's Technology
-
Stifel Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)
-
Needham & Company Reiterates Annexon Biosciences (ANNX) at Buy, Will Seek Changes in cUHRDS and NfL Levels in ANX005 Phase 1/2 trial
-
Needham & Company Reiterates Cara Therapeutics (CARA) at Buy, Expects EMA Approval of I.V. Korsuva in 2Q22
-
Needham & Company Reiterates Avidity Biosciences (RNA) at Buy
-
Needham & Company Reiterates Phathom Pharmaceuticals (PHAT) at Buy, Expects Approval of vonoprazan for H.pylori, Sees It as Laying Groundwork for Potential Approval in EE
-
Denali Therapeutics Inc. (DNLI) PT Lowered to $41 at Stifel on Lack of Short-Term Catalysts
-
Raymond James Reiterates Sarepta Therapeutics (SRPT) at Market Perform, "Risk/Reward into Pivotal Phase 3 EMBARK Data Looks Compelling"
-
Sarepta Therapeutics (SRPT) Reiterated at Buy by Needham & Company, Analyst Continues to Believe in Company's Platform and Execution
-
Needham & Company Maintains Hold Rating on Omeros (OMER), Reiterates Belief FDA Will Require Additional Trial for narsoplimab
-
Needham & Company Reiterates Jazz Pharmaceuticals (JAZZ) at Buy on Earnings, Analyst Doesn't Expect Stock to Uptick Short-Term, but Highlights Strong Execution and Fundamentals
-
William Blair Reiterates Market Perform Rating on Allakos (ALLK), Believes lirentelimab May Ultimately Be Approved but Warns of Protracted Timelines and Additional Costs
-
Needham & Company Reiterates Bicycle Therapeutics (BCYC) at Buy, Focus Remains on BT8009
-
Cowen Reiterates Allakos (ALLK) at Market Perform, Awaits More Clarity on Company's Programs
-
Atara Biotherapeutics (ATRA) PT Lowered to $20 at Stifel on Negative tab-cel Feedback from FDA, but Overall Data Seen as Supportive of Approval
-
CTI BioPharma (CTIC) PT Hiked to $8 at Needham & Company, Analyst Sees Commercial Success of VONJO with Peak Sales of $595M
